Emergence of Two Distinct Variants of SARS-CoV-2 and an Explosive Second Wave of COVID-19: the Experience of a Tertiary Care Hospital in Pune, India

Overview

Journal Arch Virol

Specialty Microbiology

Date 2022 Jan 9

PMID 35000004

Authors

Shubham Shrivastava

Suhas T Mhaske

Meera S Modak

Rashmi G Virkar

Shamburaje S Pisal

Akhilesh Chandra Mishra

Vidya A Arankalle

Affiliations

Soon will be listed here.

Abstract

The emergence of novel variants of SARS-CoV-2 in several countries has been associated with increased transmissibility or reduced neutralization potential of antibodies against the Wuhan virus (wild type). From August 2021 onwards, India experienced a progressive decline in the number of active SARS-CoV-2 infections, indicative of a downward trend in the explosive second wave. This prospective study was conducted quarterly for one year (May 2020 to June 2021) at a tertiary care hospital in the city of Pune in western India. Receptor-binding domain (RBD, n = 319) and full genome (n = 20) sequences from viral-RNA-positive nasopharyngeal swabs of COVID-19 patients representing the first and second waves were used for analysis. No Brazilian, South African, or California variants were detected in this study. Until December 2020, only the wild-type strain was prevalent. Concurrent with the upsurge of the second wave in March 2021, 73% (33/45) of RBD sequences harboured L452R/E484Q mutations characteristic of the Kappa variant. In April 2021, co-circulation of Kappa (37%) and Delta (L452R/T478K, 59%) variants was recorded. During May and June 2021, the Delta variant became the predominant circulating variant, and this coincided with a significant decline in the number of COVID-19 cases. Of the 20 full genome sequences, six isolates each exhibited signature mutations of the Kappa and Delta variant. With several states witnessing a reduction in the number of COVID-19 cases, continuous monitoring of newer mutations and assessment of their effect on virus transmissibility and their impact on vaccinated or previously exposed individuals is necessary.

Citing Articles

Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform.

Patil R, Palkar S, Mishra A, Patil R, Arankalle V Front Immunol. 2023; 14:1181991.

PMID: 37342350 PMC: 10277512. DOI: 10.3389/fimmu.2023.1181991.

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India.

Doke P, Mhaske S, Oka G, Kulkarni R, Muley V, Mishra A Front Public Health. 2023; 10:1040012.

PMID: 36711329 PMC: 9877521. DOI: 10.3389/fpubh.2022.1040012.

Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection.

Doke P, Gothankar J, Doke P, Kulkarni M, Khalate K, Shrivastava S Microbes Infect. 2022; 24(4):104979.

PMID: 35452812 PMC: 9020493. DOI: 10.1016/j.micinf.2022.104979.

References

Hoffmann M, Kleine-Weber H, Pohlmann S . A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020; 78(4):779-784.e5. PMC: 7194065. DOI: 10.1016/j.molcel.2020.04.022. View

Long S, Olsen R, Christensen P, Subedi S, Olson R, Davis J . Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. Am J Pathol. 2021; 191(6):983-992. PMC: 7962948. DOI: 10.1016/j.ajpath.2021.03.004. View

Zhang W, Davis B, Chen S, Sincuir Martinez J, Plummer J, Vail E . Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021; 325(13):1324-1326. PMC: 7879386. DOI: 10.1001/jama.2021.1612. View

Greaney A, Loes A, Crawford K, Starr T, Malone K, Chu H . Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021; 29(3):463-476.e6. PMC: 7869748. DOI: 10.1016/j.chom.2021.02.003. View

Liu Z, VanBlargan L, Bloyet L, Rothlauf P, Chen R, Stumpf S . Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021; 29(3):477-488.e4. PMC: 7839837. DOI: 10.1016/j.chom.2021.01.014. View

Sabino E, Buss L, Carvalho M, Prete Jr C, Crispim M, Fraiji N . Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021; 397(10273):452-455. PMC: 7906746. DOI: 10.1016/S0140-6736(21)00183-5. View

Claro I, Sales F, Ramundo M, Candido D, Silva C, de Jesus J . Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020. Emerg Infect Dis. 2021; 27(3):970-972. PMC: 7920684. DOI: 10.3201/eid2703.210038. View

Leung K, Shum M, Leung G, Lam T, Wu J . Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021; 26(1). PMC: 7791602. DOI: 10.2807/1560-7917.ES.2020.26.1.2002106. View

Boehm E, Kronig I, Neher R, Eckerle I, Vetter P, Kaiser L . Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021; 27(8):1109-1117. PMC: 8127517. DOI: 10.1016/j.cmi.2021.05.022. View

10.

Mlcochova P, Kemp S, Dhar M, Papa G, Meng B, Ferreira I . SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021; 599(7883):114-119. PMC: 8566220. DOI: 10.1038/s41586-021-03944-y. View

11.

Hou Y, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon 3rd K . SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020; 370(6523):1464-1468. PMC: 7775736. DOI: 10.1126/science.abe8499. View

12.

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

13.

Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K . Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592(7852):116-121. PMC: 8158177. DOI: 10.1038/s41586-020-2895-3. View

14.

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M . SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms. 2021; 9(7). PMC: 8307577. DOI: 10.3390/microorganisms9071542. View

15.

Gupta V, Bhoyar R, Jain A, Srivastava S, Upadhayay R, Imran M . Asymptomatic Reinfection in 2 Healthcare Workers From India With Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2. Clin Infect Dis. 2020; 73(9):e2823-e2825. PMC: 7543380. DOI: 10.1093/cid/ciaa1451. View

16.

Baden L, El Sahly H, Essink B, Follmann D, Neuzil K, August A . Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge. medRxiv. 2021; . PMC: 8491857. DOI: 10.1101/2021.09.17.21263624. View

17.

Peacock T, Goldhill D, Zhou J, Baillon L, Frise R, Swann O . The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol. 2021; 6(7):899-909. DOI: 10.1038/s41564-021-00908-w. View

18.

Thomson E, Rosen L, Shepherd J, Spreafico R, da Silva Filipe A, Wojcechowskyj J . Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021; 184(5):1171-1187.e20. PMC: 7843029. DOI: 10.1016/j.cell.2021.01.037. View

19.

ODowd A . Covid-19: Cases of delta variant rise by 79%, but rate of growth slows. BMJ. 2021; 373:n1596. DOI: 10.1136/bmj.n1596. View

20.

Tchesnokova V, Kulasekara H, Larson L, Bowers V, Rechkina E, Kisiela D . Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. J Clin Microbiol. 2021; 59(11):e0092121. PMC: 8525575. DOI: 10.1128/JCM.00921-21. View